It is possible that this patient's DNAJC2 carrier status could be synergistic with the VUSs in NAF1 and RTEL1. The chemotherapy that this patient received for neuroblastoma may also have contributed to the development of the MDS, in addition to an underlying TBD. Here, DNAJC2 is linked to myelodysplastic syndrome.